

Warren Mason

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10635426/publications.pdf>

Version: 2024-02-01

36
papers

14,113
citations

257450

24
h-index

361022

35
g-index

36
all docs

36
docs citations

36
times ranked

15347
citing authors

#	ARTICLE	IF	CITATIONS
1	<i>MGMT</i> Gene Silencing and Benefit from Temozolomide in Glioblastoma. <i>New England Journal of Medicine</i> , 2005, 352, 997-1003.	27.0	6,573
2	Paraneoplastic anti- <i>N-methyl-D-aspartate</i> receptor encephalitis associated with ovarian teratoma. <i>Annals of Neurology</i> , 2007, 61, 25-36.	5.3	2,166
3	Bevacizumab plus Radiotherapy vs Temozolomide for Newly Diagnosed Glioblastoma. <i>New England Journal of Medicine</i> , 2014, 370, 709-722.	27.0	2,078
4	Paraneoplastic encephalitis, psychiatric symptoms, and hypoventilation in ovarian teratoma. <i>Annals of Neurology</i> , 2005, 58, 594-604.	5.3	516
5	Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 3212-3218.	1.6	489
6	Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial Glioblastoma. <i>Journal of Clinical Oncology</i> , 2010, 28, 1168-1174.	1.6	450
7	Radiotherapy and Temozolomide for Newly Diagnosed Glioblastoma: Recursive Partitioning Analysis of the EORTC 26981/22981-NCIC CE3 Phase III Randomized Trial. <i>Journal of Clinical Oncology</i> , 2006, 24, 2563-2569.	1.6	447
8	Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 2735-2744.	1.6	244
9	A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 65, 353-361.	2.3	172
10	Phase I study of oral sonidegib (LDE225) in pediatric brain and solid tumors and a phase II study in children and adults with relapsed medulloblastoma. <i>Neuro-Oncology</i> , 2017, 19, 1542-1552.	1.2	130
11	Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma. <i>Neuro-Oncology</i> , 2014, 17, 430-9.	1.2	108
12	Emerging Biomarkers in Glioblastoma. <i>Cancers</i> , 2013, 5, 1103-1119.	3.7	80
13	Neutrophil-lymphocyte ratio dynamics during concurrent chemo-radiotherapy for glioblastoma is an independent predictor for overall survival. <i>Journal of Neuro-Oncology</i> , 2017, 132, 463-471.	2.9	78
14	Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma. <i>Neuro-Oncology</i> , 2016, 18, 1434-1441.	1.2	68
15	Impact of glycemia on survival of glioblastoma patients treated with radiation and temozolomide. <i>Journal of Neuro-Oncology</i> , 2015, 124, 119-126.	2.9	67
16	A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma. <i>Oncologist</i> , 2019, 24, 521-528.	3.7	47
17	Reversible Paraneoplastic Encephalomyelitis Associated with a Benign Ovarian Teratoma. <i>Canadian Journal of Neurological Sciences</i> , 1999, 26, 317-320.	0.5	42
18	Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy: an exploratory analysis of AVAglio. <i>Neuro-Oncology</i> , 2016, 18, 1313-1318.	1.2	39

#	ARTICLE	IF	CITATIONS
19	Bevacizumab, temozolomide, and radiotherapy for newly diagnosed glioblastoma: comprehensive safety results during and after first-line therapy. <i>Neuro-Oncology</i> , 2016, 18, 991-1001.	1.2	38
20	Prospective Quantification of CSF Biomarkers in Antibody-Mediated Encephalitis. <i>Neurology</i> , 2021, 96, e2546-e2557.	1.1	38
21	Brain Malignancy Steering Committee clinical trials planning workshop: Report from the Targeted Therapies Working Group. <i>Neuro-Oncology</i> , 2015, 17, 180-188.	1.2	28
22	ABT-888 restores sensitivity in temozolomide resistant glioma cells and xenografts. <i>PLoS ONE</i> , 2018, 13, e0202860.	2.5	28
23	Plasmatic MMP9 released from tumor-infiltrating neutrophils is predictive for bevacizumab efficacy in glioblastoma patients: an AVAglio ancillary study. <i>Acta Neuropathologica Communications</i> , 2022, 10, 1.	5.2	28
24	A phase I study of vistusertib (dual mTORC1/2 inhibitor) in patients with previously treated glioblastoma multiforme: a CCTG study. <i>Investigational New Drugs</i> , 2020, 38, 1137-1144.	2.6	26
25	Progression-free survival (PFS) and health-related quality of life (HRQoL) in AVAglio, a phase III study of bevacizumab (Bv), temozolomide (T), and radiotherapy (RT) in newly diagnosed glioblastoma (GBM).. <i>Journal of Clinical Oncology</i> , 2013, 31, 2005-2005.	1.6	26
26	Temozolomide: The evidence for its therapeutic efficacy in malignant astrocytomas. <i>Core Evidence</i> , 2009, 4, 93.	4.7	25
27	Can bevacizumab prolong survival for glioblastoma patients through multiple lines of therapy?. <i>Future Oncology</i> , 2014, 10, 1137-1145.	2.4	16
28	Neurosurgical management of adult diffuse low grade gliomas in Canada: a multi-center survey. <i>Journal of Neuro-Oncology</i> , 2016, 126, 137-149.	2.9	16
29	Marizomib alone or in combination with bevacizumab in patients with recurrent glioblastoma: Phase I/II clinical trial data. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab142.	0.7	15
30	Oculoleptomeningeal Amyloidosis Secondary to the Rare Transthyretin c.381T>G (p.Ile127Met) Mutation. <i>World Neurosurgery</i> , 2018, 111, 190-193.	1.3	14
31	Management and Outcomes in the Oldest-Old Population with Glioblastoma. <i>Canadian Journal of Neurological Sciences</i> , 2018, 45, 199-205.	0.5	10
32	Molecular Classification of Diffuse Gliomas. <i>Canadian Journal of Neurological Sciences</i> , 2020, 47, 464-473.	0.5	5
33	What are the prospects for combination therapy for glioblastoma?. <i>Expert Review of Neurotherapeutics</i> , 2017, 17, 947-949.	2.8	3
34	NANO, a practical scale for neurologic assessments in patients with brain tumors?. <i>Neuro-Oncology</i> , 2017, 19, 603-604.	1.2	2
35	Reply to T.J. Kruser et al. <i>Journal of Clinical Oncology</i> , 2016, 34, 1282-1283.	1.6	1
36	Malignant Gliomas: Present and Future Therapeutic Drugs. , 2011, , 207-214.		0